12 Benefits for Perimenopausal and Menopausal Women
Marshall Medical Group • May 19, 2025
Here are 10 potential benefits of hormonal therapy (HT) for perimenopausal women, based on current clinical evidence and expert guidelines:
1. Relieves Hot Flashes and Night Sweats
- HT is the most effective treatment for vasomotor symptoms, including hot flashes and sleep-disrupting night sweats.
2. Improves Sleep Quality
- By reducing night sweats and anxiety, HT helps many women sleep better and wake less frequently.
3. Reduces Vaginal Dryness and Discomfort
- Estrogen therapy restores vaginal tissue elasticity, moisture, and pH balance, relieving dryness, itching, and pain during intercourse.
4. Stabilizes Mood Swings
- Reduces
Anxiety, stabilizes
mood swings, and has been shown to improve symptoms of
depression.
5. Supports Cognitive Function
- HT may help preserve verbal memory and focus when started during the perimenopausal window, although evidence is mixed and individualized.
6. Helps Maintain Bone Density
- Estrogen helps prevent bone loss, reducing the risk of osteoporosis and fractures in postmenopausal years.
7. May Protect Heart Health (if started early)
- When initiated before age 60 or within 10 years of menopause, HT may lower the risk of coronary artery disease.
8. Eases Joint and Muscle Aches
- Many women report reduced joint stiffness and muscle pain, common complaints during perimenopause.
9. Enhances Skin Elasticity and Collagen
- Estrogen may modestly improve skin thickness and hydration, reducing dryness and fine lines.
10. Improves Quality of Life
- By alleviating multiple disruptive symptoms, HT can significantly improve overall well-being, energy, and daily functioning.
11. Supports Metabolic Function
- Improved insulin sensitivity, muscle maintenance, and weight stability
12. Significantly Reduces Major Health Risks
- Significantly reduces the risk of developing Coronary Artery Disease, Alzheimer's Dementia, and Osteoporosis.

The Latest Evidence: TRAVERSE Trial and Beyond The most rigorous clinical trial to date—In 2023, the TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men)—was designed specifically to answer the cardiovascular question.










